SCHEMBL21034971

SCHEMBL21034971

CC(C)(C)OC(=O)NC1CC2CCC(C1)C2C(=O)C1CN(Cc2ccc(C(F)(F)F)cc2)CCN1S(=O)(=O)c1ccc2cc(OC3CCCC3)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.38
CCR4 P51679 3/20 0.38
MMP1 P03956 3/20 0.37
MMP9 P14780 2/20 0.37
MMP13 P45452 2/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
DRD4 P21917 1/20 0.36
SCN9A Q15858 1/20 0.36
CCR2 P41597 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKAA2 P54646 1/20 0.35
MDM2 Q00987 2/20 0.34
KCNQ1 P51787 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
ADAM17 P78536 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21034935 0.88 CCR4 (0.42) ADRB2CCR4MMP1MMP9MMP13
SCHEMBL21036186 0.81 CCR4 (0.38) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21035093 0.81 CCR4 (0.38) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21036232 0.81 CCR4 (0.38) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21035452 0.79 CCR4 (0.40) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21035343 0.79 CCR4 (0.42) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21035330 0.79 CCR4 (0.42) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21035072 0.79 CCR4 (0.42) CCR4MMP1MMP9MMP13MMP3
SCHEMBL21035481 0.77 ADRB2 (0.43) ADRB2CCR4MMP1MMP9MMP13
SCHEMBL21035477 0.77 ADRB2 (0.43) ADRB2CCR4MMP1MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed